Mon, Sep 22, 2014, 10:19 AM EDT - U.S. Markets close in 5 hrs 41 mins

Recent

% | $
Quotes you view appear here for quick access.

Pharmacyclics Inc. Message Board

  • maxcoatinc maxcoatinc Oct 14, 2013 2:58 PM Flag

    Will JNJ earnings and management statements about Ibrutinib have a greater influence on PCYC

    price direction than GILD news had on PCYC, which in the end was very little. It is still all about what the large mutual funds holding such as Fidelity BIOTECH and others do with PCYC.

    MAX

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • YES.On Friday, Goldman Sachs analyst Jami Rubin upgraded the stock to neutral from sell, noting that the success of several recent drug launches bodes well for simeprevir and ibrutinib, two products currently awaiting FDA approval. Simeprevir is a hepatitis C drug that J&J eventually hopes to combine with a drug it just acquired from GlaxoSmithKline (GSK) to form an all-oral therapy for hepatitis C. Ibrutinib is a treatment for blood cancer developed by Pharmacyclics (PCYC), which won a "breakthrough therapy" designation from the FDA to speed up its review process.

      Despite some good news about Gilead Sciences ' (GILD) rival idelalisib drug last week, Goldman Sachs analyst Navdeep Singh set his peak annual sales estimate for ibrutinib at $7.5 billion.

      Sentiment: Strong Buy

      • 1 Reply to jgmtruth
      • OK...so GILD's HepC is predicted avg. "PEAK SALES" of $7.4B :) The big buzz now surrounds Gilead's hepatitis C drug Sofosbuvir. Already touted as a megablockbuster, an FDA decision on sofosbuvir is expected in December, around the time competitor Johnson & Johnson hears about its simeprevir. The average analyst estimate for peak sales of sofosbuvir is $7.4 billion.

        And Idelalisib..is just icing on the cake..:)))) GLTA big market for both!! :))

 
PCYC
121.76-1.76(-1.42%)10:19 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.